Systemic sclerosis & Raynaud's
Risk of Malnutrition in Patients With Systemic Sclerosis‐Associated Interstitial Lung Disease Treated With Nintedanib in the Randomized, Placebo‐Controlled SENSCIS Trial
Authors' conclusion
In the SENSCIS trial, most patients with SSc-ILD remained at low risk of malnutrition over 52 weeks, but the proportion at high risk was higher in patients who received treatment with nintedanib compared to those who received placebo.
Study context
- Population
- Patients with SSc-ILD randomised in the SENSCIS trial, subgroups by baseline body mass index (BMI) ≤20 kg/m² and >20 kg/m²subgroups by baseline BMI ≤20 kg/m² 61 · >20 kg/m² 515
- Comparison
- Nintedanib vs placebo
- Primary endpoint
- Adverse events (AEs) by baseline BMI subgroup and risk of malnutrition (modified Malnutrition Universal Screening Tool (MUST))
- Follow-up
- 52 weeks
Methodological detailsplacebo-controlled, subgroup analysis by baseline BMI
- Placebo-controlled
- Subgroup analysis by baseline BMI
Primary result
As reported in the abstract
AEs leading to treatment discontinuation, by baseline BMI subgroup
BMI ≤20 kg/m²
BMI >20 kg/m²
Further findings
Low risk of malnutrition (modified MUST) at baseline and at last assessment · 52 weeks
Low risk of malnutrition at baseline but high risk by last assessment (modified MUST) · 52 weeks
Original publication
Risk of Malnutrition in Patients With Systemic Sclerosis‐Associated Interstitial Lung Disease Treated With Nintedanib in the Randomized, Placebo‐Controlled SENSCIS Trial. Arthritis Care Res (Hoboken). Published 7 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →